Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Labeling for CBER-Regulated Products

Labeling for CBER-Regulated Products

                        About the Advertising and Promotional Labeling Branch (APLB)
          Submitting Biologics Advertising & Promotional Labeling
          Compliance Actions on Biologics Advertising & Promotional Labeling
          Proprietary Name Review for Biologic Products
          Regulatory Information about Biologics Advertising & Promotional Labeling Home
          Vaccines, Blood & Biologics
          Development & Approval Process (CBER)
          Labeling for CBER-Regulated Products
          Bar Code Label Requirements for Blood and Blood Components Questions and AnswersLabeling for CBER-Regulated Products Bar Code Label Requirements for Blood and Blood Components Questions and Answers
  
  	
    Share
    Post
    Linkedin

    Email
    Print**Is it true that we must label blood and blood components with specific machine-readable bar code information by April 26th, 2006?**

Yes, under the bar code label requirements final rule of Feb 26, 2004, products subject to the rule, including blood and blood components intended for transfusion, must be in compliance by April 26, 2006. The regulation for blood and blood components is located at 21 CFR 606.121(c)(13). The final rule is entitled: Bar Code Label Requirement for Human Drug Products and Biological Products (69 Federal Register 9120, February 26, 2004).

**What machine-readable information is required for blood and blood components?**

21 CFR 606.121(c)(13)(ii-iii) states the container label must bear encoded information in a format that is machine-readable and approved for use by the Director, Center for Biologics Evaluation and Research.

Currently, two types of machine-readable label types are recognized by FDA: FDA recognized the use of Codabar (a specific bar code symbology) in 1985; and FDA accepted the use of ISBT 128, version 1.2.0, in 2000. CBER has recognized the second version (2.0.0.) effective September 22, 2006. Please see "Guidance for Industry:  Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels" as well as the new ISBT 128 Uniform Labeling document.

Each label must have at a minimum: (A) A unique facility identifier; (B) Lot number relating to the donor; (C) Product code; and, (D) ABO and Rh of the donor.

**We are a transfusion service and very infrequently prepare split units, pediatric units, and pooled cryoprecipitate units; do we need machine-readable labels for these units?**

Yes, This situation was described in the preamble to the proposed rule (68 Federal Register 12500 at 12513):"The unit of blood or blood component label would contain the machine-readable information if the blood or blood component has any possibility of being transfused to a patient, whether or not the unit is actually transfused. Additionally, the phrase, "from which the blood or blood component can be taken and transfused to a patient" would include the circumstance where blood or a blood component is extracted or aspirated with a syringe from the container of blood or blood component in order to transfuse to a patient. This technique might be used when transfusing neonates or under other medically necessitated circumstances. In this case, the blood or blood component from which the aspirate is taken must have affixed to it a label containing the required machine-readable information. This would be consistent with the pre-existing requirement at § 606.121(c)(8)(iii) that requires specific statements if a product is intended for transfusion."

**I have questions about how to encode facility identifiers and product codes for pooled and aliquoted units for Codabar or ISBT 128? Where do I get information about these issues?**

Please contact CBER's Manufacturers Assistance and Technical Training Branch (MATTB) at industry.biologics@fda.gov for additional information. The regulation requires a unique facility identifier.

**How will FDA evaluate compliance with the rule?**

Our investigators will evaluate compliance with these regulations during routine inspections of blood establishments.

**May I request an exception or alternative under 21 CFR 640.120 for this requirement of the blood and blood component container label regulations?**

The purpose of the bar coding rule is to reduce transfusion errors and increase patient safety. CBER will carefully review any request for exception or alternative. The bar code regulation for drug products recognizes that exemptions may be warranted when compliance would adversely affect the drug's safety, effectiveness, purity or potency or not be technologically feasible. In the preamble to the rule discussing exemptions for drug products, FDA noted that almost all drug products are capable of bearing a bar code. FDA noted that we would not consider written requests based on reasons such as financial reasons, a claimed low rate of medication errors, or a claim that the product is unique such that medication errors do not occur or rarely occur. In assessing requests for exemptions for blood and blood components, FDA would follow the same approach as that described in the drug regulations (21 CFR 201.25(d)).

                                                                                  Content current as of:
      03/16/2018Labeling for CBER-Regulated Products

          
                        About the Advertising and Promotional Labeling Branch (APLB)
          Submitting Biologics Advertising & Promotional Labeling
          Compliance Actions on Biologics Advertising & Promotional Labeling
          Proprietary Name Review for Biologic Products
          Regulatory Information about Biologics Advertising & Promotional Labeling
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop